These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17097981)

  • 21. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients.
    Testa G; Crippin JS; Netto GJ; Goldstein RM; Jennings LW; Brkic BS; Brooks BK; Levy MF; Gonwa TA; Klintmalm GB
    Liver Transpl; 2000 Sep; 6(5):553-61. PubMed ID: 10980053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved liver function and decreased hepatitis C viral load after tacrolimus was replaced by cyclosporine.
    Lorho R; Turlin B; de Lajarte-Thirouard AS; Camus C; Lakehal M; Compagnon P; Meunier B; Boudjema K; Messner M
    Transplant Proc; 2005; 37(6):2871-2. PubMed ID: 16182838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of anti-hepatitis C virus (HCV) antibody on outcomes in renal transplant recipients infected with HCV.
    Minz M; Sharma A; Das A; Chawla Y
    Transplant Proc; 2008 Sep; 40(7):2386-8. PubMed ID: 18790242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral load speaks little about toll on liver.
    Mahtab MA; Rahman S; Khan M; Kamal M; Mamun AA; Karim MF
    Hepatobiliary Pancreat Dis Int; 2007 Oct; 6(5):483-6. PubMed ID: 17897910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticosteroid-free immunosuppression in pediatric liver transplantation: safety and efficacy after a short-term follow-up.
    Cintorino D; Riva S; Spada M; Minervini M; Sonzogni A; Foglieni CS; Gruttadauria S; Verzaro R; Henderson K; Aricò M; Gridelli B
    Transplant Proc; 2006 May; 38(4):1099-100. PubMed ID: 16757276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
    Firpi RJ; Zhu H; Morelli G; Abdelmalek MF; Soldevila-Pico C; Machicao VI; Cabrera R; Reed AI; Liu C; Nelson DR
    Liver Transpl; 2006 Jan; 12(1):51-7. PubMed ID: 16382464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.
    Sheiner PA; Schwartz ME; Mor E; Schluger LK; Theise N; Kishikawa K; Kolesnikov V; Bodenheimer H; Emre S; Miller CM
    Hepatology; 1995 Jan; 21(1):30-4. PubMed ID: 7806166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
    Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
    Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
    Jacob DA; Neumann UP; Bahra M; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serial measurements of hepatitis C viral load by real-time polymerase chain reaction among recipients of living-donor renal transplants: a short-term follow-up study from a single center.
    Justa S; Minz RW; Minz M; Sharma A; Anand S; Das A; Chawla YK; Sakhuja VK
    Transplant Proc; 2010 Nov; 42(9):3568-73. PubMed ID: 21094817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BK virus in liver transplant recipients: a prospective study.
    Loeches B; Valerio M; Pérez M; Bañares R; Ledesma J; Fogeda M; Salcedo M; Rincón D; Bouza E; Muñoz P;
    Transplant Proc; 2009 Apr; 41(3):1033-7. PubMed ID: 19376419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
    Pillet A; Mengelle C; Basse G; Ribes D; Kamar N; Muscari F; Lavayssière L; Suc B; Esposito L; Peron JM; Rostaing L
    Transplant Proc; 2006 Sep; 38(7):2335-8. PubMed ID: 16980083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C.
    Ciccorossi P; Maina AM; Oliveri F; Petruccelli S; Leandro G; Colombatto P; Moriconi F; Mosca F; Filipponi F; Bonino F; Brunetto MR
    Liver Int; 2007 Jun; 27(5):612-9. PubMed ID: 17498245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.
    Yosry A; Esmat G; El-Serafy M; Omar A; Doss W; Said M; Abdel-Bary A; Hosny A; Marawan I; El-Malt O; Kamel RR; Hatata Y; Ghali A; Sabri H; Kamel S; El-Gbaly H; Tanaka K
    Transplant Proc; 2008 Jun; 40(5):1481-4. PubMed ID: 18589133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
    Villamil F; Levy G; Grazi GL; Mies S; Samuel D; Sanjuan F; Rossi M; Lake J; Munn S; Mühlbacher F; Leonardi L; Cillo U
    Transplant Proc; 2006 Nov; 38(9):2964-7. PubMed ID: 17112875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation.
    Langrehr JM; Puhl G; Bahra M; Schmeding M; Spinelli A; Berg T; Schönemann C; Krenn V; Neuhaus P; Neumann UP
    Liver Transpl; 2006 Apr; 12(4):644-51. PubMed ID: 16555324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection.
    Kuo A; Tan V; Lan B; Khalili M; Feng S; Roberts JP; Terrault NA
    Liver Transpl; 2008 Oct; 14(10):1491-7. PubMed ID: 18825708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis.
    Samonakis DN; Cholongitas E; Thalheimer U; Kalambokis G; Quaglia A; Triantos CK; Mela M; Manousou P; Senzolo M; Dhillon AP; Patch D; Burroughs AK
    Liver Transpl; 2007 Sep; 13(9):1305-11. PubMed ID: 17763383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation.
    De Ruvo N; Cucchetti A; Lauro A; Masetti M; Cautero N; Di Benedetto F; Dazzi A; Del Gaudio M; Ravaioli M; Zanello M; La Barba G; di Francesco F; Risaliti A; Ramacciato G; Pinna AD
    Transplant Proc; 2005; 37(6):2607-8. PubMed ID: 16182760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.